Dazopride is an antagonist of the 5-HT3 receptor and agonist of the 5-HT4 receptor, structurally related to metoclopramide. Dazopride was developed by A. H. Robins Company as an antiemetic and gastroprokinetic drug. Dazoptide demonstrated an antiemetic effect in the clinic after i.v. infusion to patients, receiving anticancer therapy.

Deramciclane is camphor derivative. It is an anxiolytic agent that binds with high affinity to 5-HT2A/2C receptor. Deramciclane showed significant evidence of efficacy for the treatment of generalized anxiety disorder in adult patients. A single dose of deramciclane was rapidly absorbed with peak plasma concentrations being reached after about 3 h. Deramciclane has a half-life of around 27 h. The most commonly reported adverse event was headache. In the in vitro studies deramciclane concentration-dependently inhibited NMDA evoked spreading depression.

3-Aminopropionitrile (beta-aminopropionitrile, BAPN) is a poisonous substance found in Lathyrus spp. (wild peas), for example, Lathyrus hirsutus (wild winter pea), sometimes sown with grasses to provide early-spring grazing. BAPN is a specific and irreversible inhibitor of LOX activity. It has been shown to reduce body weight gain and improve the metabolic profile in diet-induced obesity in rats. The administration of beta-aminopropionitrile has been proposed for pharmacological control of unwanted scar tissue in human beings. BAPN has been shown to have preventive effect in the development of fibrosis by decreasing tissue damage in an experimental model of corrosive esophagitis in rats. BAPN is FDA approved for the treatment of tendinitis of the superficial digital flexor tendon (SDFT) in horses where there is sonographic evidence of fiber tearing.

FEZOLAMINE is a nontricyclic antidepressant. It acts as a serotonin, norepinephrine, and dopamine reuptake inhibitor, with a preference for the former neurotransmitter. It was found to be effective and well tolerated in clinical trials but was never marketed.

Fluocinolone participated in clinical trials for the treatment of Oral Lichen Planus and Candida Infection.

BIPHENYL DIMETHYL DICARBOXYLATE (BDD) under the brand name Nissel is used in the South Corea for the treatment of chronic hepatitis followed by an increase in serum alanine aminotransferase levels continuously. This compound also participated in clinical trials phase III in the patients with chronic liver disease. In addition, the drug was studied in phase III clinical trials after laparoscopic cholecystectomy. The use of BDD in patients with cholecystitis was expected to inhibit elevated liver enzyme levels and to maintain liver function.

F-15599 is a novel agonist with high selectivity and efficacy at serotonin 5-HT(1A) receptors. In signal transduction, electrophysiological and neurochemical tests, F-15599 preferentially activates post-synaptic 5-HT(1A)Rs in rat frontal cortex. Such a profile may translate to an improved profile of therapeutic activity for mood disorders. [(18)F]F-15599 is a radiofluorinated agonist presenting interesting characteristics for probing in vitro and in vivo the high-affinity states of the 5-HT(1A) receptors. The Rett Syndrome Research Trust awarded a grant to Neurolixis to advance F-15599 to clinical development.